Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-15
2011-03-15
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800
Reexamination Certificate
active
07906479
ABSTRACT:
The invention provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans.
REFERENCES:
patent: 5019383 (1991-05-01), Hopp
patent: 5134122 (1992-07-01), Orsolini
patent: 5445832 (1995-08-01), Orsolini et al.
patent: 5637568 (1997-06-01), Orsolini et al.
patent: 5643455 (1997-07-01), Kopp et al.
patent: 5658840 (1997-08-01), Kölle et al.
patent: 5663145 (1997-09-01), Engel et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5889110 (1999-03-01), Hutchinson
patent: 5942493 (1999-08-01), Kutscher et al.
patent: 5968895 (1999-10-01), Gefter et al.
patent: 6258933 (2001-07-01), Günther et al.
patent: 6780972 (2004-08-01), Damm et al.
patent: 2002/0198146 (2002-12-01), Damm et al.
patent: 2002/0198186 (2002-12-01), Engel et al.
patent: 2004/0259801 (2004-12-01), Damm et al.
patent: 2006/0135405 (2006-06-01), Rischer et al.
patent: 1447817 (2003-10-01), None
patent: 136916 (2004-02-01), None
patent: 38 22 459 (1989-03-01), None
patent: 42 23 282 (1993-01-01), None
patent: 42 23 284 (1993-01-01), None
patent: 43 42 092 (1995-06-01), None
patent: 100 40 700 (2002-02-01), None
patent: 0 947 200 (1999-10-01), None
patent: WO 95/15767 (1995-06-01), None
patent: WO 99/07164 (1999-02-01), None
patent: WO 00/47234 (2000-08-01), None
patent: WO 01/87265 (2001-11-01), None
patent: WO 02/14347 (2002-02-01), None
patent: WO 03/022243 (2003-03-01), None
Product monograph. Cetrotide.Cetrorelix acetate for injection. Accessed online on Aug. 1, 2009 at http://www.emdserono.ca/cmg.emdserono—ca/en/images/Cetrotide—Prescribing—Information—tcm463—17891.pdf . 2003. pp. 1-21.
H. M. Behre, et al., “GnRH antagonists: an overview”, The Proceedings of the 2ndWorld Conference on Ovulation Induction, Cover Page and pp. 107-113, Sep. 12-13, 1997.
P. L. Bigliardi, et al., “Anaphylaxis to the Carbohydrate Carboxymethylcellulose in Parenteral Corticosteroid Preparations”, Dermatology, vol. 207, 2003, pp. 100-103.
C. Battaglia, et al., “Doppler analysis of uterine blood flow changes in spontaneous and medically induced menopause”, Gynecological Endocrinology, vol. 9, 1995, pp. 143-148.
A. Reron, et al., “The effect of hormonal factors on the hearing organ in women, after surgical castration. Preliminary Report.”, Neuroendocrinology Letters, vol. 23, Nos. 5/6, Oct.-Dec. 2002, pp. 455-458.
Robert G. Strickley, “Solubilizing Excipients in Oral and Injectable Formulations”, Pharmaceutical Research, vol. 21, No. 2, Feb. 2004, pp. 201-230.
K. Stoeckemann, et al., “Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[α]anthracene-induced mammary carcinoma: studies with slow-release formulations”, Journal of Cancer Research and Clinical Oncology, vol. 119, 1993, pp. 457-462.
Roland Oppliger, et al, “Anaphylaxis after injection of corticosteroid preparations—carboxymethylcellulose as a hidden allergen”, JDDG, vol. 2, 2004, pp. 928-930 (with English summary).
Bernhard Kutscher, et al., “Chemistry and Molecular Biology in the Search for New LHRH Antagonists”, Angew. Chem. Int. Ed. Engl., vol. 36, 1997, pp. 2149-2161.
Kavitha Koushik, et al., “Preparation of Large Porous Deslorelin-PLGA Microparticles with Reduced Residual Solvent and Cellular Uptake Using a Supercritical Carbon Dioxide Process”, Pharmaceutical Research, vol. 21, No. 3, Mar. 2004, pp. 524-535.
M. Kaufmann, et al., “Goserelin, a Depot Gonadotrophin-Releasing Hormone Agonist in the Treatment of Premenopausal Patients With Metastatic Breast Cancer”, Journal of Clinical Oncology, vol. 7, No. 8, Aug. 1989, pp. 1113-1119.
“Impurities in New Drug Products Q3B(R2)”, ICH Harmonised Tripartite Guideline, Jun. 2, 2006, 3 Cover Pages and pp. 1-12.
“Impurities: Guideline for Residual Solvents Q3C(R3)”, ICH Harmonised Tripartite Guideline, Nov. 2005, 3 Cover Pages and pp. 1-20.
“Annex 12 Use of Ionising Radiation in the Manufacture of Medicinal Products”, EC Guide to Good Manufacturing Practices, pp. 115-120.
“Manufacture of Sterile Medicinal Products”, EC Guide to Good Manufacturing Practice Revision to Annex 1, May 30, 2003, 12 pages.
R. E. Felberbaum, “Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix”, Human Reproduction, vol. 13, No. 6, 1998, pp. 1660-1668.
Dirk L. Teagarden, et al., “Practical aspects of lyophilization using non-aqueous co-solvent systems”, European Journal of Pharmaceutical Sciences, vol. 15, 2002, pp. 115-133.
Fiedler—Lexikon Der Hilfsstoffe für Pharmazie, Kosmetik und Angrenzende Gebiete (5th edition 2002), pp. 97-114.
Engel Juergen
Mueller Horst
Rischer Matthias
Werner Karl
Cordero Garcia Marcela M
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Zentraris GmbH
LandOfFree
Sterile suspensions of slightly soluble basic peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sterile suspensions of slightly soluble basic peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sterile suspensions of slightly soluble basic peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720766